<DOC>
	<DOCNO>NCT00003058</DOCNO>
	<brief_summary>Troglitazone may help liposarcoma cell develop normal cell . This single arm , open-label study two-stage design evaluate troglitazone patient liposarcoma stratify histologic subtype .</brief_summary>
	<brief_title>Troglitazone Treating Patients With Liposarcoma</brief_title>
	<detailed_description>OBJECTIVES : I . To evaluate clinical activity troglitazone patient malignant liposarcoma stratify histologic subtype . II . To perform correlative imaging , biological , biochemical test patient order define degree vivo terminal differentiation may promote therapeutic intervention . III . To evaluate tolerance safety troglitazone patient population . PROJECTED ACCRUAL : Initially , 14 patient 5 histologic subtypes liposarcoma accrue . If 1 patient show evidence biological response , additional 16 patient subtype accrue total 30 patient per subtype . If 4 30 patient achieve biological response troglitazone deem promising histologic subtype .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Liposarcoma</mesh_term>
	<mesh_term>Troglitazone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven liposarcoma incurable standard surgery Measurable evaluable disease require No active CNS involvement leptomeningeal disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL SGOT le 5 time upper normal limit Renal : Creatinine great 2.0 mg/dL Cardiovascular : No poorly control atrial arrhythmia , angina pectoris , myocardial infarction within past 6 month No symptomatic congestive heart failure , percutaneous transluminal coronary angioplasty , coronary artery bypass graft within past 3 month Other : Not pregnant nursing Fertile patient must use effective contraception No known active retroviral disease PRIOR CONCURRENT THERAPY : Recovered toxic effect prior therapy No concurrent cytotoxic therapy Biologic therapy : Not specify Chemotherapy : Prior chemotherapy allow Endocrine therapy : No concurrent hormonal therapy Radiotherapy : Prior radiation therapy metastatic disease allow No radiotherapy sole site measurable disease within past 6 month Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>adult liposarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
</DOC>